• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Influence of dyslipidemia in control of arterial hypertension among type-2 diabetics in the western region of the Republic of Macedonia.血脂异常对马其顿共和国西部地区2型糖尿病患者动脉高血压控制情况的影响。
Am J Cardiovasc Dis. 2014 Jun 28;4(2):58-69. eCollection 2014.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies.血压和血脂管理在 2 型糖尿病患者中远远不足:来自包括六项德国基于人群研究的 DIAB-CORE 联盟的结果。
Cardiovasc Diabetol. 2012 May 8;11:50. doi: 10.1186/1475-2840-11-50.
4
Level of unawareness and management of diabetes, hypertension, and dyslipidemia among adults in Luxembourg: findings from ORISCAV-LUX study.卢森堡成年人的糖尿病、高血压和血脂异常知晓率及管理情况:ORISCAV-LUX 研究结果。
PLoS One. 2013;8(3):e57920. doi: 10.1371/journal.pone.0057920. Epub 2013 Mar 4.
5
6
[Pharmacological therapy of obesity].[肥胖症的药物治疗]
G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S.
7
[Cardiovascular risk profile in 40-year old men and 50-year old women in the Czech Republic: results of a cross-sectional survey].[捷克共和国40岁男性和50岁女性的心血管风险状况:一项横断面调查的结果]
Vnitr Lek. 2014 Nov;60(11):991-7.
8
Personal attributes that influence the adequate management of hypertension and dyslipidemia in patients with type 2 diabetes. Results from the DIAB-CORE Cooperation.影响 2 型糖尿病患者高血压和血脂异常合理管理的个体特征。DIAB-CORE 合作研究结果。
Cardiovasc Diabetol. 2012 Oct 5;11:120. doi: 10.1186/1475-2840-11-120.
9
Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study.土耳其成年人血脂异常及相关危险因素的患病率:特拉布宗血脂研究
Endocrine. 2008 Aug-Dec;34(1-3):36-51. doi: 10.1007/s12020-008-9100-z. Epub 2008 Nov 12.
10

引用本文的文献

1
Patient-level factors influencing hypertension control in adults in Accra, Ghana.加纳阿克拉成年人高血压控制的患者层面影响因素。
BMC Cardiovasc Disord. 2020 Mar 11;20(1):123. doi: 10.1186/s12872-020-01370-y.

本文引用的文献

1
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013年美国心脏病学会/美国心脏协会成人降低动脉粥样硬化性心血管风险的血胆固醇治疗指南:美国心脏病学会/美国心脏协会实践指南工作组报告
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934. doi: 10.1016/j.jacc.2013.11.002. Epub 2013 Nov 12.
2
Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies.血压和血脂管理在 2 型糖尿病患者中远远不足:来自包括六项德国基于人群研究的 DIAB-CORE 联盟的结果。
Cardiovasc Diabetol. 2012 May 8;11:50. doi: 10.1186/1475-2840-11-50.
3
Sub-optimal achievement of guideline-derived lipid goals in management of diabetes patients with atherosclerotic cardiovascular disease, despite high use of evidence-based therapies.尽管使用了大量的循证疗法,但在治疗伴有动脉粥样硬化性心血管疾病的糖尿病患者时,指南指导下的血脂目标仍未得到充分实现。
Diab Vasc Dis Res. 2012 Apr;9(2):138-45. doi: 10.1177/1479164111431471. Epub 2012 Jan 10.
4
Hypertension management in diabetic patients.糖尿病患者的高血压管理。
Eur Rev Med Pharmacol Sci. 2011 Nov;15(11):1256-63.
5
Hypertension in people with type 2 diabetes: Update on pharmacologic management.2 型糖尿病患者的高血压:药物治疗管理的最新进展。
Can Fam Physician. 2011 Sep;57(9):997-1002, e347-53.
6
Lipid-lowering therapy: who can benefit?降脂治疗:谁能获益?
Vasc Health Risk Manag. 2011;7:525-34. doi: 10.2147/VHRM.S23113. Epub 2011 Aug 24.
7
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).ESC/EAS 血脂异常管理指南:欧洲心脏病学会(ESC)和欧洲动脉粥样硬化学会(EAS)血脂异常管理工作组
Eur Heart J. 2011 Jul;32(14):1769-818. doi: 10.1093/eurheartj/ehr158. Epub 2011 Jun 28.
8
Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008.美国糖尿病患者人群中,1999-2008 年期间,降血脂药物和降血压药物的使用趋势和目标达标情况。
Cardiovasc Diabetol. 2011 Apr 17;10:31. doi: 10.1186/1475-2840-10-31.
9
Patient adherence to medication requirements for therapy of type 2 diabetes.患者对 2 型糖尿病治疗药物要求的依从性。
Int J Clin Pract. 2011 Mar;65(3):314-22. doi: 10.1111/j.1742-1241.2010.02544.x.
10
Atherosclerotic disease location and disparities in the control and treatment of cardiovascular risk factors in patients with Type 2 diabetes.2 型糖尿病患者的动脉粥样硬化病变位置与心血管危险因素控制和治疗的差异。
Diabet Med. 2010 Mar;27(3):303-8. doi: 10.1111/j.1464-5491.2010.02952.x.

血脂异常对马其顿共和国西部地区2型糖尿病患者动脉高血压控制情况的影响。

Influence of dyslipidemia in control of arterial hypertension among type-2 diabetics in the western region of the Republic of Macedonia.

作者信息

Jani Ylber, Kamberi Amet, Ferati Fatmir, Rexhepi Atila, Pocesta Bekim, Orovcanec Nikola, Lala Dali, Polisi Gafur, Iseni Mair, Mirto Arben, Zeqiri Agim

机构信息

Department of Cardiology, Faculty of Medicine, "Mother Teresa" University Tirana, Republic of Albania.

Department of Internal Medicine, Faculty of Medicine Tetov.

出版信息

Am J Cardiovasc Dis. 2014 Jun 28;4(2):58-69. eCollection 2014.

PMID:25006533
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4082230/
Abstract

OBJECTIVE

To determine the influence of dyslipidemia in control of blood pressure in patients with type 2 Diabetes. To test the hypothesis that, blood pressure and lipid levels are not sufficiently controlled in patients with type 2 Diabetes, in the western region of the Republic of Macedonia.

BACKGROUND

Abnormalities of lipid and lipoprotein levels in the serum (dyslipidemia) are recognized as major modifiable cardiovascular disease risk factors and have been identified as independent risk factors for essential hypertension, giving rise to the term dyslipidemic hypertension. While patient-related data from primary care that demonstrate an under-treatment of blood pressure and dyslipidemia in type 2 Diabetics are vastly available in clinical practice, results from population-based studies are scarce.

MATERIAL AND METHODS

The study was conducted on outpatients in Primary Health Care Clinics in 8 cities on the western region of the Republic of Macedonia. Prospectively the tests were performed on 600 (45.6% women and 54.4% men) participants with a mean age of 62 ± 5.8. Study participants were selected among primary care patients, who were actively on therapy for diabetes mellitus and hypertension during the period of March 2013 - March 2014. Patients' demographic characteristics, clinical laboratory and drug usage data were obtained. The patients were classified according to the BP control, into 2 groups.

RESULTS

A total of 600 patients, of which 45.6% female and 54.3% male, completed the survey and had data for a 1-year medical record review. It was observed that a high percentage, 65.3% of patients, did not have controlled blood pressure despite the ongoing medical treatment, according to evidence and current guidelines in a cohort of hypertensive diabetics. (Chi-square: 19.85, p<0.001). Among participants with controled BP, untreated or insufficiently treated dyslipidemia was recorded in 23% of them, whereas among participants with uncontrolled BP, untreated or insufficiently treated dyslipidemia was recorded in 67% of the participants. (Chi-square: 15.01, p=0.0001).

CONCLUSION

A significant influence of dyslipidemia on the control of blood pressure in patients with type 2 Diabetes, was observed in our study. In a small country as Republic of Macedonia (with a population of around 2.000.000, especially the western region with approximately 1/2 of the overall population), this study highlights the considerable lack of awareness and insufficient management of the most important preventable and treatable cardiovascular risk factors (hypertension and dyslipidemia). These findings provide a possible explanation of the steadily high cardiovascular mortality rate despite the clinical and therapeutic progress and accessibility. Besides current hospital-based prevention and pharmaceutical control measures, mass education campaigns, lifestyle interventions etc., emphasis should be given to the role of family doctor as a primary-care health provider.

摘要

目的

确定血脂异常对2型糖尿病患者血压控制的影响。验证如下假设:在马其顿共和国西部地区,2型糖尿病患者的血压和血脂水平未得到充分控制。

背景

血清中脂质和脂蛋白水平异常(血脂异常)被认为是主要的可改变心血管疾病风险因素,并且已被确定为原发性高血压的独立风险因素,由此产生了“血脂异常性高血压”这一术语。虽然在临床实践中,大量来自初级保健的患者相关数据表明2型糖尿病患者的血压和血脂治疗不足,但基于人群的研究结果却很少。

材料与方法

该研究在马其顿共和国西部地区8个城市的初级卫生保健诊所的门诊患者中进行。前瞻性地对600名(45.6%为女性,54.4%为男性)平均年龄为62±5.8岁的参与者进行了检测。研究参与者是从2013年3月至2014年3月期间积极接受糖尿病和高血压治疗的初级保健患者中挑选出来的。获取了患者的人口统计学特征、临床实验室和药物使用数据。根据血压控制情况将患者分为2组。

结果

共有600名患者完成了调查并拥有1年病历审查的数据,其中45.6%为女性,54.3%为男性。根据高血压糖尿病患者队列的证据和现行指南观察到,尽管正在进行治疗,但仍有65.3%的患者血压未得到控制。(卡方检验:19.85,p<0.001)。在血压得到控制的参与者中,23%的人存在未经治疗或治疗不充分的血脂异常,而在血压未得到控制的参与者中,67%的人存在未经治疗或治疗不充分的血脂异常。(卡方检验:15.01,p = 0.0001)。

结论

在我们的研究中观察到血脂异常对2型糖尿病患者的血压控制有显著影响。在像马其顿共和国这样的小国(人口约200万,特别是西部地区约占总人口的一半),这项研究突出了对最重要的可预防和可治疗心血管风险因素(高血压和血脂异常)的认识严重不足和管理不力的情况。这些发现为尽管有临床和治疗进展以及可及性,但心血管死亡率持续居高不下提供了一种可能的解释。除了当前基于医院的预防和药物控制措施、大众教育活动、生活方式干预等之外,还应重视家庭医生作为初级保健提供者的作用。